|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Caliper Life Sciences Inc., of Hopkinton, Mass., said its wholly owned subsidiary Xenogen Biosciences signed a target validation collaboration with Kenilworth, N.J.-based Schering-Plough Corp. to provide access to its Serial Phenotyping Compression Technology to characterize target results from drug discovery research conducted at the Schering-Plough Research Institute. Financial terms of the deal were not disclosed.
o Centocor Inc., of Malvern, Pa., and Schering-Plough Corp., of Kenilworth, N.J., clarified the question regarding the expiration date for Schering-Plough's rights to market golimumab worldwide, excluding the U.S., Japan and other Asian markets, ...